Cypherpunk Technologies Inc. (CYPH) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 11, 2025, covers events related to a Special Meeting of stockholders held on December 15, 2025. The company, formerly known as Leap Therapeutics, Inc., is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol CYPH.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses on corporate governance actions and regulatory compliance status.
Material Changes and Corporate Actions
- Charter Amendment: Stockholders approved an amendment to the Certificate of Incorporation, increasing the total authorized shares from 250,000,000 to 500,000,000. This includes 490,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock.
- Equity Incentive Plan: The 2025 Equity Incentive Plan was adopted, authorizing grants covering up to 31,454,785 shares of Common Stock.
- Reverse Stock Split: Stockholders voted to approve a reverse stock split proposal.
- Private Placement: Stockholders eligible to vote approved a private placement issuance proposal.
- Nasdaq Compliance: The company received notification from Nasdaq on December 11, 2025, confirming it has regained compliance with the minimum bid price requirement (Rule 5550(a)(2)), closing a matter that began in March 2025.
Voting Results
| Proposal | Votes For | Votes Against | Votes Abstaining |
|---|---|---|---|
| Authorized Share Increase | 29,990,904 | 4,121,627 | 18,538 |
| Reverse Stock Split | 36,314,864 | 4,935,206 | 691,181 |
| 2025 Equity Incentive Plan | 28,765,316 | 5,105,626 | 260,130 |
| Private Placement Issuance | 17,403,379 | 1,361,238 | 154,144 |
| Adjournment of Meeting | 35,080,571 | 6,571,932 | 288,748 |
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the previously noted Nasdaq listing compliance issue, which has now been resolved. The company is designated as an emerging growth company.
Key Facts for Investor Verification
- Verify the effective date and specific terms of the reverse stock split, as the filing confirms approval but does not detail the split ratio or implementation date.
- Review the full text of the 2025 Equity Incentive Plan (Exhibit 10.1) to understand vesting schedules and eligibility criteria for the 31.4 million authorized shares.
- Confirm the details of the approved private placement issuance, including the number of shares to be issued and the price per share, as these specifics are not detailed in this summary.
- Monitor the company's stock price to ensure continued compliance with Nasdaq listing requirements following the recent resolution of the bid price deficiency.